Review decision – May 2018
Decision to move the existing guidance to the static list
We would like to update you on the decision made regarding the review of the existing guidance on TA335; Rivaroxaban for the prevention of adverse outcomes in patients after the acute management of acute coronary syndrome.
Evidence published since NICE technology appraisal 335 supports the committee’s considerations and addresses some of the uncertainties identified in the appraisal. There has not been any evidence identified that suggests a review of this guidance is necessary.
NICE’s Guidance Executive has decided to proceed with this proposal without consultation.
Consequently TA355 will move to the ‘static list’ of technology appraisals.
In addition to this, NICE is bringing together four existing clinical guidelines to form one new guideline on acute coronary syndromes. As part of this work, TA335 can be incorporated into the new guideline. More information on this update is available from our website.
This page was last updated: 17 May 2018